|
Published by: Frost & Sullivan
Published: Sep. 1, 2001
Table of Contents
1. Executive Summary
A. Market Overview
1. Introduction
2. Introduction
A. Overview
1. Scope and Segmentation
2. Epidemiology and Etiology
3. Staging of Prostate Cancer
4. Market Trends
5. Technology Trends- Gene Therapy
6. Technology Trends- Others
B. Market Dynamics
1. Top Three Challenges
2. Challenges - Others
3. Top Three Drivers
4. Drivers - Others
5. Top Three Restraints
6. Restraints - Others
C. Strategic Recommendations
1. Strategies Overview
2. Strategic Recommendations for Market Challenge 1
3. Strategic Recommendations for Market hallenge 2
4. Strategic Recommendations for Market Challenge 3
5. Strategic Recommendations for Market Challenge 4
6. Strategic Recommendations for Market Challenge 5
7. Strategic Recommendations for Market Challenge 6
D. Frost & Sullivan Market Engineering Awards
1. Technology Innovation Award
2. Strategic Alliance Leadership Award
3. Technology Leadership Award.
4. Website Leadership Award
5. Entrepreneurial Company Award
3. Localized Prostate Cancer Therapeutics Market
A. Overview
1. Introduction
2. Existing Therapies
3. Other Therapies
4. Market Engineering Analysis
B. Forecasts and Trends
1. Demand Analysis
2. Revenue Forecasts
3. Pricing Trends
C. Competitive Analysis
1. Competitive Structure
2. Market Share Analysis
3. Product Analysis-Existing Products
4. Product Analysis-Emerging Products: Hormones and Chemotherapeutics
5. Product Analysis-Emerging Products: Immunotherapeutics
4. Locally Advanced Prostate Cancer Therapeutics Market
A. Overview
1. Introduction
2. Existing Therapies
3. Investigational Therapies
4. Market Engineering Analysis
B. Forecasts and Trends
1. Demand Analysis
2. Revenue Forecast Model and Assumptions
3. Revenue Forecasts
4. Current Pricing Trends
5. Future Pricing Trends
C. Competitive Analysis
1. Competitive Structure
2. Market Share Analysis
3. Product Analysis-Existing Products
4. Product Analysis-Emerging Products: Hormones
5. Product Analysis-Emerging Products: Chemotherapeutics and Others
6. Product Analysis-Emerging Products: Immunotherapeutics
5. Metastatic Prostate Cancer Therapeutics Market
A. Overview
1. Introduction
2. Existing Therapies - Hormones and Other AAI's
3. Existing Therapies - Chemotherapy
4. Future Therapies
5. Market Engineering Analysis
B. Forecasts and Trends
1. Demand Analysis
2. Revenue Forecast Model and Assumptions
3. Revenue Forecast
4. Current Pricing Trends
5. Future Pricing Trends
C. Competitive Analysis
1. Competitive Structure
2. Market Share Analysis
3. Product Analysis-Existing Products
4. Product Analysis-Emerging Products: Hormones
5. Product Analysis-Emerging Products: Chemotherapeutics and Others
6. Products Analysis-Emerging Products: Immunotherapeutics
7. Product Analysis-Other Emerging Products
List of Figures
Chapter 2
Emerging Prostate Cancer Therapeutics Market: Estimated Age-Adjusted Incidence and Mortality Rates per 100,000 of the Population (U.S.), 2000
Emerging Prostate Cancer Therapeutics Market: Estimated Incidence and Mortality Rates of Prostate Cancer by Race/Ethnicity (U.S.), 2000
Emerging Prostate Cancer Therapeutics Market: Prostate Cancer Staging (Stage I-II) (U.S.), 2000
Emerging Prostate Cancer Therapeutics Market: Prostate Cancer Staging (Stage III-IV) (U.S.), 2000
Emerging Prostate Cancer Therapeutics Market: Survival Rate in Prostate Cancer (U.S.), 2000
Emerging Prostate Cancer Therapeutics Market: Impact of Top Industry Challenges (U.S.), 2001-2007
Emerging Prostate Cancer Therapeutics Market: Market Drivers Ranked in Order of Impact (U.S.), 2001-2007
Emerging Prostate Cancer Therapeutics Market: Market Restraints Ranked in Order of Impact (U.S.), 2000-2007
Emerging Prostate Cancer Therapeutics Market: Strategies Addressing Market Challenges (U.S.), 2000
Chapter 3
Emerging Prostate Cancer Therapeutics Market: Incidence and Mortality Rates per 100,000 of the Population (U.S.), 2000
Emerging Prostate Cancer Therapeutics Market: Total Male Population (35 years and older) and Prostate Cancer Incidences and Mortality (U.S.), 1997-2007
Emerging Prostate Cancer Therapeutics Market: Total Treated Prostate Cancer Population and Total Treated Localized Prostate Cancer Population (U.S.), 1997-2007
Localized Prostate Cancer Therapeutics Market: Hormone Revenue Forecasts (U.S.), 1997-2007
Localized Prostate Cancer Therapeutics Market: Revenue Forecasts (U.S.), 1997-2007
Localized Prostate Cancer Therapeutics Market: Percent of Revenues by Product Type (U.S.), 1997-2007
Localized Prostate Cancer Therapeutics Market: Product Pricing (U.S.), 2000
Localized Prostate Cancer Therapeutics Market: Competitive Structure (U.S.), 2000
Localized Prostate Cancer Therapeutics Market: Market Share Analysis (U.S.), 2000
Localized Prostate Cancer Therapeutics Market: Product Analysis--Marketed Products (U.S.), 2000
Localized Prostate Cancer Therapeutics Market: Product Analysis--Hormones and Chemotherapeutics (U.S.), 2000
Localized Prostate Cancer Therapeutics Market: Product Analysis-- Immunotherapeutics (U.S.), 2000
Chapter 4
Locally Advanced Prostate Cancer Therapeutics Market: Total Prostate Cancer Population and Total Locally Advanced Prostate Cancer Population (U.S.), 1997-2007
Locally Advanced Prostate Cancer Therapeutics Market: Hormone Revenue Forecasts (U.S.), 1997-2007
Locally Advanced Prostate Cancer Therapeutics Market: Revenue Forecasts (U.S.), 1997-2007
Locally Advanced Prostate Cancer Therapeutics Market: Percent of Revenues by Product Type (U.S.), 1997-2007
Locally Advanced Prostate Cancer Therapeutics Market: Product Pricing (U.S.), 2000.
Locally Advanced Prostate Cancer Therapeutics Market: Competitive Structure (U.S.), 2000
Locally Advanced Prostate Cancer Therapeutics Market: Market Share Analysis (U.S.), 2000
Locally Advanced Prostate Cancer Therapeutics Market: Product Analysis, Existing Products (U.S.), 2000
Locally Advanced Prostate Cancer Therapeutics Market: Product Analysis, Emerging Products--Hormones (U.S.), 2000
Locally Advanced Prostate Cancer Therapeutics Market: Product Analysis, Emerging Products--Chemotherapeutics and Others (U.S.), 2000
Locally Advanced Prostate Cancer Therapeutics Market: Product Analysis, Emerging Products—Immunotherapeutics (U.S.), 2000
Chapter 5
Metastatic Prostate Cancer Therapeutics Market: Total Prostate Cancer Population and Total Metastatic Prostate Cancer Population (U.S.), 1997-2007
Metastatic Prostate Cancer Therapeutics Market: Hormone Revenue Forecasts (U.S.), 1997-2007
Metastatic Prostate Cancer Therapeutics Market: Revenue Forecasts (U.S.), 1997-2007
Metastatic Prostate Cancer Therapeutics Market: Percent of Revenues by Product Type (U.S.), 1997-2007
Metastatic Prostate Cancer Therapeutics Market: Product Pricing (U.S.), 2000
AbstractProstate Cancer Cases to Rise as Baby Boomers Age
Next to skin cancer, prostate cancer is the second most common cancer for men within the United States. The risk of developing the disease significantly increases at age 50. By 2007, it is estimated that the male population in the U.S. over 50 years old will reach 41 million, substantially expanding the pool of prostate cancer patients and driving demand for reliable therapies with
limited side effects.
This Frost & Sullivan research provides an in-depth analysis of the U.S. emerging prostate therapeutics markets. By identifying market drivers and supplying strategic recommendations, this study offers your company a comprehensive guide to the future of this burgeoning field.
Devlopment of New Products with Fewer Adverse Patient Reactions Drives Market
Existing therapies for prostate cancer may be effective in managing the disease, but patient expectations with regards to toxicity and side effects are clearly not being satisfied. The urgent medical need for treatments that prolong survival with fewer side effects and improved quality of life is spurring research and development activity.
"Promoting a product based on superior anti-tumor activity, with less toxicity and without compromising the quality of life of patients, is going to be key to
the success of any newly approved product," says the author of this research.
Widespread Media Coverage Increases Public Knowledge, Encourages Early Diagnoses
Prostate cancer traditionally was not a topic men felt comfortable discussing, and generally ignored the calls for early testing. However, as public knowledge and education continues to develop, the opportunity for diagnosis is becoming easier, increasing the number of patients requiring medical attention.
"Prostate cancer has now taken on a visibility similar to breast cancer and has become a popular subject of discussion in the media. Screening for prostate cancer is becoming almost as easy and accessible as checking one's cholesterol levels with testing booths set up in public locations," states the author.
This Frost & Sullivan analysis provides up-to-date market intelligence, enabling the reader to take advantage of key opportunities and formulate a successful
business plan within the U.S. emerging prostate cancer therapeutic markets.
Get Full Details About This Report >>
|
